Table 2.
Characteristics of the patients and explanation method of the two evaluating methods (18F-FDG PET/CT and MRI).
| Author | County | Year | Initial clinical stage | Histology subtype | Receptor status | Parameter of PET/CT | Parameter of MRI | Reconstruction or not | Image interpretation | Cut-off value of PET/CT | Cut-off value of MRI |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pengel et al. [23] | Netherlands | 2014 | II (49) III (41) IVa (3) |
IDC (85) ILC (7) Others (1) |
HER-2(+) (25) ER(+)/PR(−) (4) Triple(−) (28) |
ROI + SUVmax | ROI + diameter | Yes | NR | Reduction > 50% | Reduction > 75% (D) |
| Kim et al. [22] | Korea | 2014 | II (24) III (33) IVa (2) |
IDC (54) ILC (1) MC (1) |
NR | ROI + SUVmax | ROI + diameter ROI + volume |
Yes | Blind | Reduction > 60.1% | Reduction > 50% (D) Reduction > 68.9% (V) |
| Tateishi et al. [21] | Japan | 2012 | Ia (9) II (95) III (38) |
IDC (131) ILC (11) |
ER(+) (100) PR(+) (82) HER-2(+) (111) |
ROI + SUVmax | ROI + Kep | Yes | NR | Reduction > 50% | Reduction > 30% (D) |
| Park et al. [20] | Korea | 2011 | NR | IDC (31) MC (1) |
ER(+) (14) PR(+) (13) |
ROI + SUVmax | ROI + diameter | Yes | Blind | Reduction > 50% | Reduction > 30% (D) |
| Choi et al. [19] | Korea | 2010 | II, III | IDC (36) ILC (2) MC (1) Other (2) |
ER(+) (19) PR(+) (15) HER-2(+) (10) |
ROI + pSUV | ROI + diameter | NR | Blind | Reduction > 50% | Reduction > 30% (D) |
| Chen et al. [18] | USA | 2004 | LABC | IDC (12) ILC (3) MC (1) |
ER(+) (12) PR(+) (11) HER-2(+) (2) |
ROI + SUVmax | ROI + diameter | Yes | Blind | Reduction > 50% | Reduction > 30% (D) |
LABC: local advanced breast cancer.
IDC: invasive ductal carcinomas.
ILC: invasive lobular carcinomas.
MC: metaplastic carcinoma.
ER: estrogen receptor.
PR: progesterone receptor.
ROI: region of interest.
D: diameter.
V: volume.
NR: not reported.